Oncology · Monoclonal AntibodyRegulatory Approvalregulatorymid-term

FDA Accepts Supplement Application for DARZALEX (Daratumumab)

Importance7/ 10

ActionMonitor

View Company Intelligence

Explore aggregated signals, assets, and competitive context for organizations linked to this signal.

Janssen36 signalsView page

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 7/21/2026, 6:32:37 AM

Assessment confidence: 53% · The main uncertainty is limited high-relevance corpus coverage for this sub-indication.

Executive Thesis

The FDA's acceptance of the supplemental application for DARZALEX is a significant regulatory milestone that could strengthen Janssen's competitive position in the oncology market. Portfolio teams must stay alert to potential shifts in market dynamics and competitor strategies as the review progresses. Regulatory context from FDA (FDA AP — DARZALEX (SUPPL)) supports the near-term read. Assessment grounded in 24 ranked evidence items (4 high-relevance).

Strategic Assessment

Portfolio teams should prepare for potential market shifts and assess competitive responses from other monoclonal antibody therapies. The strongest clinical anchor is Palliative Care Integration in Pediatric Oncology Phase 1 Clinical Trials (ClinicalTrials.gov), moderate corpus alignment. In Oncology · Monoclonal Antibody, 6 regulatory and 4 competitive items passed relevance filtering for Janssen.

Competitive Pressure

The most relevant competitive pressure comes from FDA Approves Supplemental Application for Retevmo (Selpercatinib) (Humanexa Signals) — sponsor/company relevance (lilly). Secondary pressure from FDA Grants Priority Review for ABBVIE's BLA761460 (DECNUPAZ). This acceptance may enhance Janssen's position in the oncology market, particularly in multiple myeloma treatments.

Regulatory Outlook

Regulatory risk is concentrated around FDA AP — DARZALEX (SUPPL) (FDA). Entity match (janssen). The acceptance of the supplemental application indicates a pathway towards potential approval, which could lead to expanded indications for DARZALEX, influencing compliance and labeling.

Key Risks

Elevated medium regulatory exposure for Janssen could delay market entry or constrain labeling if agency review intensifies.

Key Opportunities

If approved, this supplemental application could enhance DARZALEX's market share in multiple myeloma, impacting revenue streams and competitive positioning against other therapies.
Upside for Janssen may improve if Tislelizumab (Anti-Programmed Cell Death Protein-1 (PD-1) Antibody) in MSI-H or dMMR Solid Tumors (ClinicalTrials.gov) delivers favorable follow-through.
Upside for Janssen may improve if Combination therapy with a novel CD2-targeted costimulatory bispecific antibody overcomes limitations of CD3 T cell engager treatment for solid tumors. (PubMed) delivers favorable follow-through.
Upside for Janssen may improve if Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma (ClinicalTrials.gov) delivers favorable follow-through.
Oncology · HER2-positive Breast Cancer · Regulatory Approval · This approval enhances Genentech's position in the HER2-positive breast cancer market, potentially increasing market share against competitors.

What Would Change This Assessment

This becomes more urgent if Monitor the timeline for FDA review and any subsequent announcements regarding approval outcomes.
Additional medium- or high-relevance evidence would materially upgrade this assessment.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

FDA AP — DARZALEX (SUPPL)
FDAhigh relevance
Entity match (janssen)
FDA document
View source
FDA AP — SPORANOX (SUPPL)
FDAhigh relevance
Entity match (janssen)
FDA document
View source
FDA AP — ERLEADA (SUPPL)
FDAhigh relevance
Entity match (janssen)
FDA document
View source
IND Application Reporting: IND Safety Reports
FDAmedium relevance
Moderate corpus alignment
FDA document
View source
Investigational New Drug (IND) Application
FDAmedium relevance
Moderate corpus alignment
FDA document
View source
FDA AP — PADCEV (SUPPL)
FDAmedium relevance
Moderate corpus alignment
FDA document
View source

Palliative Care Integration in Pediatric Oncology Phase 1 Clinical Trials
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Tislelizumab (Anti-Programmed Cell Death Protein-1 (PD-1) Antibody) in MSI-H or dMMR Solid Tumors
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Multiple Micronutrient Supplementation for Maternal Anemia Prevention in Tanzania
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Follow-Up Evaluation for Gene-Therapy-Related Delayed Adverse Events After Participation in Pediatric Oncology Branch Clinical Trials
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Hydrus® Microstent New Enrollment Post-Approval Study
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Natural History Study of Monoclonal B Cell Lymphocytosis (MBL), Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Lymphoplasmacytic Lymphoma (LPL)/Waldenstrom Macroglobulinemia (WM),
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source

FDA Approves Supplemental Application for Retevmo (Selpercatinib)
Humanexa Signalshigh relevance
Sponsor/company relevance (Lilly)
FDA Grants Priority Review for ABBVIE's BLA761460 (DECNUPAZ)
Humanexa Signalsmedium relevance
Moderate corpus alignment
FDA Approves HERCEPTIN HYLECTA Supplement Application
Humanexa Signalsmedium relevance
Moderate corpus alignment
FDA Grants Priority Review for Tecentriq Hybreza Supplement Application
Humanexa Signalsmedium relevance
Moderate corpus alignment

Trial watch: antibody-drug conjugates in cancer therapy.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
NMR detects clustering and ultra-weak excipient interactions governing monoclonal antibody viscosity in formulation-relevant conditions.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Combination therapy with a novel CD2-targeted costimulatory bispecific antibody overcomes limitations of CD3 T cell engager treatment for solid tumors.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Selected immunoendocrine and performance adaptations to upper-body plyometric training and β-alanine supplementation in male swimmers.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Intratumoral enrichment and suppressive activity of DP8α regulatory T cells in human colorectal cancer.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Rarely reported cases of hepatotoxicity associated with turmeric- and curcuminoid-containing dietary supplements: a comprehensive review by USP.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

Janssen
DARZALEX
competing monoclonal antibodies

Commercial impact

medium

If approved, this supplemental application could enhance DARZALEX's market share in multiple myeloma, impacting revenue streams and competitive positioning against other therapies.

Regulatory impact

medium

The acceptance of the supplemental application indicates a pathway towards potential approval, which could lead to expanded indications for DARZALEX, influencing compliance and labeling.

What to watch

Monitor the timeline for FDA review and any subsequent announcements regarding approval outcomes.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.